Wall Street brokerages predict that FibroGen Inc (NASDAQ:FGEN) will report sales of $47.10 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for FibroGen’s earnings. The highest sales estimate is $52.70 million and the lowest is $37.70 million. FibroGen posted sales of $27.27 million during the same quarter last year, which would indicate a positive year over year growth rate of 72.7%. The company is scheduled to report its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that FibroGen will report full-year sales of $185.07 million for the current fiscal year, with estimates ranging from $135.40 million to $256.80 million. For the next financial year, analysts anticipate that the firm will post sales of $204.00 million, with estimates ranging from $92.00 million to $278.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for FibroGen.
FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.31. The company had revenue of $43.95 million for the quarter, compared to analysts’ expectations of $28.70 million. FibroGen had a negative return on equity of 22.60% and a negative net margin of 85.59%.
Several analysts have commented on the stock. BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 15th. Zacks Investment Research upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Citigroup lowered shares of FibroGen from a “buy” rating to a “hold” rating and set a $71.00 price objective for the company. in a report on Wednesday, August 8th. ValuEngine upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 21st. Finally, Mizuho restated a “buy” rating and issued a $74.00 price objective on shares of FibroGen in a report on Wednesday, August 8th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $75.67.
In other news, CEO Thomas B. Neff sold 18,900 shares of FibroGen stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $56.75, for a total transaction of $1,072,575.00. Following the completion of the transaction, the chief executive officer now directly owns 2,761,894 shares in the company, valued at $156,737,484.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roberto Pedro Rosenkranz sold 1,000 shares of FibroGen stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $56.95, for a total transaction of $56,950.00. Following the transaction, the director now owns 33,700 shares of the company’s stock, valued at $1,919,215. The disclosure for this sale can be found here. Insiders sold 263,409 shares of company stock valued at $15,990,227 over the last 90 days. 8.96% of the stock is currently owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in FGEN. Aperio Group LLC purchased a new position in shares of FibroGen during the first quarter valued at approximately $207,000. Thrivent Financial for Lutherans purchased a new position in shares of FibroGen during the first quarter valued at approximately $874,000. New York State Common Retirement Fund lifted its holdings in shares of FibroGen by 12.9% during the first quarter. New York State Common Retirement Fund now owns 77,850 shares of the biopharmaceutical company’s stock valued at $3,597,000 after purchasing an additional 8,900 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of FibroGen by 78,059.5% during the first quarter. PNC Financial Services Group Inc. now owns 28,919 shares of the biopharmaceutical company’s stock valued at $1,337,000 after purchasing an additional 28,882 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of FibroGen by 87.8% during the first quarter. Russell Investments Group Ltd. now owns 8,810 shares of the biopharmaceutical company’s stock valued at $407,000 after purchasing an additional 4,118 shares during the last quarter. Hedge funds and other institutional investors own 76.06% of the company’s stock.
FGEN traded down $3.73 on Thursday, hitting $54.20. The company had a trading volume of 889,297 shares, compared to its average volume of 504,538. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.95 and a quick ratio of 7.95. FibroGen has a 52-week low of $40.74 and a 52-week high of $68.55. The firm has a market capitalization of $5.12 billion, a PE ratio of -31.33 and a beta of 1.81.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Further Reading: What is the Dividend Aristocrat Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.